AMENDMENTS TO THE CLAIMS

1. (Original) A pharmaceutical composition comprising an effective amount of a prostaglandin D_2 related substance for the regulation of food intake.

2. (Original) A pharmaceutical composition comprising an effective amount of prostaglandin D_2 or a prostaglandin D_2 agonist for the stimulation of food intake.

3. (Original) A pharmaceutical composition comprising an effective amount of a prostaglandin D_2 antagonist for the inhibition of food intake.

4. (Original) The pharmaceutical composition according to Claim 3 wherein said prostaglandin D_2 antagonist is a compound of the formula:



or a pharmaceutically acceptable salt thereof, or a solvate thereof.

5. (Original) The pharmaceutical composition according to Claim 3 wherein said prostaglandin D_2 antagonist is a compound of the formula (I):



(I)

wherein



is (A) or (B) ;

R is hydrogen, alkyl, alkoxy, halogen, hydroxy, acyloxy or optionally substituted arylsulfonyloxy;

X is hydrogen or alkyl; and

the double bond on the alpha-chain has E configuration or Z configuration

or a pharmaceutically acceptable salt thereof, or a solvate thereof.

6. (Original) The pharmaceutical composition according to Claim 5 wherein said prostaglandin D_2 antagonist is a compound of the formula (IB):



(IB)

wherein

R and X are as defined above; and

the double bond on the alpha-chain has E configuration or Z configuration

or a pharmaceutically acceptable salt thereof, or a solvate thereof.

7. (Original) The pharmaceutical composition according to Claim 5 wherein said prostaglandin D_2 antagonist is a compound of the formula (IA-a):



(IA-a)

wherein

R and X are as defined above; and

the double bond on the alpha-chain has E configuration or Z configuration

or a pharmaceutically acceptable salt thereof, or a solvate thereof.

8. (Original) The pharmaceutical composition according to Claim 7 wherein said prostaglandin D_2 antagonist is a compound of the formula (IA-a1):



(IA-a1)

or a pharmaceutically acceptable salt thereof, or a solvate thereof.

9. (Original) A method for regulating food intake in a mammal including human, comprising administering to said mammal an effective amount of prostaglandin D_2 related substance.

10. (Original) A method for stimulating food intake in a mammal including human, comprising administering to said mammal an effective amount of prostaglandin D_2 or a prostaglandin D_2 agonist.

11. (Original) A method for inhibiting food intake in a mammal including human, comprising administering to said mammal an effective amount of a prostaglandin D_2 antagonist.

12. (Original) The method according to Claim 11 wherein said prostaglandin D_2 antagonist is a compound of the formula:



or a pharmaceutically acceptable salt thereof, or a solvate thereof.

13. (Original) The method according to Claim 11 wherein said prostaglandin D_2 antagonist is a compound of the formula (I):



(I)

wherein



is



(A) or



(B) ;

R is hydrogen, alkyl, alkoxy, halogen, hydroxy, acyloxy or optionally substituted arylsulfonyloxy;

X is hydrogen or alkyl; and

the double bond on the alpha-chain has E configuration or Z configuration or a pharmaceutically acceptable salt thereof, or a solvate thereof.

14. (Original) The method according to Claim 13 wherein said prostaglandin D_2 antagonist is a compound of the formula (IB):



(IB)

wherein

R and X are as defined above; and

the double bond on the alpha-chain has E configuration or Z configuration or a pharmaceutically acceptable salt thereof, or a solvate thereof.

15. (Original) The method according to Claim 13 wherein said prostaglandin D_2 antagonist is a compound of the formula (IA-a):



(IA-a)

wherein

R and X are as defined above; and

the double bond on the alpha-chain has E configuration or Z configuration or a pharmaceutically acceptable salt thereof, or a solvate thereof.

16. (Original) The method according to Claim 15 wherein said prostaglandin D_2 antagonist is a compound of the formula (IA-a1):



(IA-a1)

or a pharmaceutically acceptable salt thereof, or a solvate thereof.

17-24. (Cancelled)